{"id":49778,"date":"2025-12-02T22:09:40","date_gmt":"2025-12-02T14:09:40","guid":{"rendered":"https:\/\/flcube.com\/?p=49778"},"modified":"2025-12-02T22:09:42","modified_gmt":"2025-12-02T14:09:42","slug":"abbvie-rinvoq-upadacitinib-cde-priority-review-alopecia-areata-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49778","title":{"rendered":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China"},"content":{"rendered":"\n<p><strong>AbbVie<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced that <strong>Rinvoq<\/strong> (upadacitinib) has been included in the <strong>priority review list<\/strong> by the Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) for <strong>severe alopecia areata<\/strong> in adults and adolescents aged 12 and above.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-indication\">Regulatory Milestone &amp; Indication<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AbbVie (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Rinvoq (upadacitinib)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>CDE Priority Review (China)<\/td><\/tr><tr><td><strong>Proposed Indication<\/strong><\/td><td>Severe alopecia areata (age \u226512 years)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Third priority review designation for upadacitinib in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: Selective JAK inhibitor<\/li>\n\n\n\n<li><strong>First US Approval<\/strong>: 2019<\/li>\n\n\n\n<li><strong>China Market Entry<\/strong>: 2022<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Targets JAK-STAT pathways to modulate immune-mediated inflammatory responses<\/li>\n\n\n\n<li><strong>Formulation<\/strong>: Oral tablet<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-china-approved-indications-portfolio\">China Approved Indications Portfolio<\/h2>\n\n\n\n<p>Upadacitinib is currently approved in China for <strong>eight immune-mediated inflammatory disease indications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Atopic dermatitis<\/li>\n\n\n\n<li>Rheumatoid arthritis<\/li>\n\n\n\n<li>Psoriatic arthritis<\/li>\n\n\n\n<li>Ulcerative colitis<\/li>\n\n\n\n<li>Crohn&#8217;s disease<\/li>\n\n\n\n<li>Ankylosing spondylitis<\/li>\n\n\n\n<li>Non-radiographic axial spondyloarthritis<\/li>\n\n\n\n<li>Giant cell arteritis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-implications\">Strategic Context &amp; Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alopecia Areata Market<\/strong>: China has ~4 million patients; severe cases lack approved oral therapies<\/li>\n\n\n\n<li><strong>Priority Review Pathway<\/strong>: Accelerates NMPA review timeline from 12-18 months to 6-8 months<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: First JAK inhibitor for alopecia areata in China; potential 2026 launch<\/li>\n\n\n\n<li><strong>Revenue Impact<\/strong>: Analysts project China peak sales potential of <strong>$200-300 million<\/strong> for this indication<\/li>\n\n\n\n<li><strong>Global Portfolio<\/strong>: Strengthens AbbVie&#8217;s leadership in immunology with fifth major indication<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, market potential, and commercial prospects for upadacitinib. Actual results may differ due to regulatory, competitive, and market access uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,853,80],"class_list":["post-49778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-nyse-abbv","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49778\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49778\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T14:09:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T14:09:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China\",\"datePublished\":\"2025-12-02T14:09:40+00:00\",\"dateModified\":\"2025-12-02T14:09:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0206.webp\",\"keywords\":[\"AbbVie\",\"NYSE: ABBV\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49778#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49778\",\"name\":\"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0206.webp\",\"datePublished\":\"2025-12-02T14:09:40+00:00\",\"dateModified\":\"2025-12-02T14:09:42+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49778\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0206.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0206.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49778#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49778","og_locale":"en_US","og_type":"article","og_title":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China","og_description":"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.","og_url":"https:\/\/flcube.com\/?p=49778","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-02T14:09:40+00:00","article_modified_time":"2025-12-02T14:09:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49778#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49778"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China","datePublished":"2025-12-02T14:09:40+00:00","dateModified":"2025-12-02T14:09:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49778"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49778#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","keywords":["AbbVie","NYSE: ABBV","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49778#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49778","url":"https:\/\/flcube.com\/?p=49778","name":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49778#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49778#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","datePublished":"2025-12-02T14:09:40+00:00","dateModified":"2025-12-02T14:09:42+00:00","description":"AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for severe alopecia areata in adults and adolescents aged 12 and above.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49778#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49778"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49778#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","width":1080,"height":608,"caption":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49778#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0206.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49778"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49778\/revisions"}],"predecessor-version":[{"id":49782,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49778\/revisions\/49782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49781"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}